| Objective To investigate the incidence of adverse reactions in patients with multi-drug resistant pulmonary tuberculosis during the medication. Methods The clinical data of 76 patients with multi-drug resistant pulmonary tuberculosis admitted to our hospital from February 2014 to February 2017 were retrospectively analyzed, and the incidence of adverse reactions was counted. Results The enrolled 76 patients with multi-drug resistant pulmonary tuberculosis in this group had 60 case and 68 case-times adverse reactions. The top 3 adverse reactions were gastrointestinal reactions, arthralgia or muscle pain and liver toxicity, accounting for 25.00%, 17.11% and 14.47%, respectively. There were no statistically significant differences in the incidence of adverse reactions among patients with different gender, age, household registration, and whether they were initially treated multi-drug resistant pulmonary tuberculosis patients (P ＞ 0.05). Among 68 adverse reactions, there were 60 patients in total, 34 patients of them needed to maintain the original treatment, accounting for 56.67%; 18 patients of them needed dose adjustment or drug replacement, accounting for 30.00%; and 8 patients of them needed to stop treatment, accounting for 11.76%. Conclusions The incidence of adverse reactions in patients with multi-drug resistant pulmonary tuberculosis is high during treatment. However, through close and timely observations on the occurrence of adverse reactions and the understanding of relevant criteria and indications, most patients can continue to receive treatment, and drug withdrawal or treatment discontinuance should not be performed at will. |